

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

AU565

RRID:CVCL_1074

Type: Cell Line

Proper Citation

RRID:CVCL_1074

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1074

Proper Citation: RRID:CVCL_1074

Description: Cell line AU565 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: [PMID:17157791](#), [PMID:18516279](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29273624](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MET genetic alteration cell panel (ATCC TCP-1036)., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AU565

Synonyms: AU-565, AU 565

Cross References: BTO:BTO_0004737, CLO:CLO_0001769, EFO:EFO_0001087, AddexBio:C0006010/4900, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-2351, BioGRID_ORCS_Cell_line:333, BioSample:SAMN03470878, BioSample:SAMN03471449,

BioSample:SAMN10987882, cancercellines:CVCL_1074,
Cell_Model_Passport:SIDM00898, ChEMBL-Cells:ChEMBL3308095, ChEMBL-
Targets:ChEMBL1075393, CLS:305313, Cosmic:687462, Cosmic:910704,
Cosmic:1136358, Cosmic:1176652, Cosmic:1309002, Cosmic:1995342, Cosmic:2165002,
Cosmic-CLP:910704, DepMap:ACH-000248, EGA:EGAS00001000978, GDSC:910704,
GEO:GSM274658, GEO:GSM344340, GEO:GSM344390, GEO:GSM843441,
GEO:GSM843442, GEO:GSM847196, GEO:GSM847451, GEO:GSM886871,
GEO:GSM887936, GEO:GSM1053701, GEO:GSM1172851, GEO:GSM1172939,
GEO:GSM1238118, GEO:GSM1421428, GEO:GSM1669605, GEO:GSM2258812,
GEO:GSM2258813, GEO:GSM2258814, GEO:GSM2258815, GEO:GSM2258816,
GEO:GSM2258817, GEO:GSM2258818, GEO:GSM2258819, GEO:GSM2258820,
GEO:GSM2258821, GEO:GSM2258822, GEO:GSM2258823, GEO:GSM2258824,
GEO:GSM2258825, GEO:GSM2258826, GEO:GSM2258827, GEO:GSM2258828,
GEO:GSM2258829, GEO:GSM2258923, GEO:GSM2258924, GEO:GSM2258925,
IARC_TP53:21178, LiGeA:CCLE_052, LINCS_HMS:50091, LINCS_LDP:LCL-1462,
PharmacoDB:AU565_70_2019, PRIDE:PXD030304, Progenetix:CVCL_1074,
PubChem_Cell_line:CVCL_1074, SLKBase:3384, Wikidata:Q54751885

ID: CVCL_1074

Record Creation Time: 20220427T215229+0000

Record Last Update: 20260904T021359+0000

Ratings and Alerts

No rating or validation information has been found for AU565.

No alerts have been found for AU565.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. *Neoplasia* (New York, N.Y.), 78, 101318.

Ghosh S, et al. (2026) Export of miRNAs from activated macrophages is cooperative and HuR-dependent. *FEBS letters*, 600(5), 693.

Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. *The Journal of biological chemistry*, 302(4), 111302.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. *International journal of cancer*, 156(8), 1606.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

Burnham CM, et al. (2025) An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. *bioRxiv : the preprint server for biology*.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Wu R, et al. (2025) Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer. *Cancer letters*, 627, 217823.

Roberts SE, et al. (2024) Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles. *iScience*, 27(8), 110461.

Li J, et al. (2024) Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting. *Molecular cell*.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Lin WD, et al. (2024) A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer. *Cell death & disease*, 15(5), 310.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Zhang W, et al. (2023) AEP-cleaved DDX3X induces alternative RNA splicing events to mediate cancer cell adaptation in harsh microenvironments. *The Journal of clinical investigation*, 134(3).

Johnson BE, et al. (2022) An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. *Cell reports. Medicine*, 3(2), 100525.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.

Wei B, et al. (2021) GABAB1e promotes the malignancy of human cancer cells by targeting the tyrosine phosphatase PTPN12. *iScience*, 24(11), 103311.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.